Arylbenzoisoxazole compounds as ip6k and ipmk inhibitors and methods of use thereof
OwnerXiaodong Wang, Yubai Zhouinventors
Life of this patent
Estimating the term…
Abstract
Arylbenzoisoxazole compounds of Formula II, where R1 and R2 are defined herein, are useful for inhibiting isoforms of IP6K and IPMK, and for treating diseases and disorders such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cancer, and viral infections. Methods of using compounds of Formula II for prevention or treatment of such diseases and disorders, pharmaceutical compositions comprising the compounds, and methods of preparing the compounds are also disclosed.
Claims31
A compound of Formula II:
- or a pharmaceutically acceptable salt thereof, wherein
- X is aryl or heteroaryl;
- R3 is, in each instance, selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, -D, —OH, —OR5, —NH—COR6, —CONR7R8, —SO2—NHR9, and NR10R11
- p is an integer from 0 to 5;
- Y is present or absent, and when present selected from the group consisting of alkyl, cycloalkyl, and alkenyl;
- and
- R4 is selected from the group consisting of —CO2H, —CO2R5, —CONR7R8, —SO2—NHR6, —SO3H, —P(O)(OH)(OR9), heteroaryl, and heterocycloalkyl;
- wherein
- R5 is selected from alkyl, aryl, heteroaryl, and heterocycloalkyl;
- R6 is selected from alkyl, cycloalkyl, aryl, and heteroaryl;
- R7 and R8 are each independently selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
- R9 is selected from alkyl, aryl, heteroaryl, and heterocycloalkyl;
- and R10 and R11 are each independently selected from hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A compound having one of the following structures:
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.